DK1228071T3 - Farmaceutisk aktive isoindolinderivater - Google Patents

Farmaceutisk aktive isoindolinderivater

Info

Publication number: DK1228071T3
Authority: DK; Denmark
Prior art keywords: pharmaceutically active; isoindoline derivatives; active isoindoline; derivatives; oxoisoindoline
Prior art date: 1999-11-12

Application number

DK00977095T

Other languages

Danish (da)

English (en)

Inventor

Hon-Wah Man

George Muller

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-12

Filing date

2000-11-09

Publication date

2007-08-06

2000-11-09 Application filed by Celgene Corp filed Critical Celgene Corp

2007-08-06 Application granted granted Critical

2007-08-06 Publication of DK1228071T3 publication Critical patent/DK1228071T3/da

Links

GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical class C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 title 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
QDZOBXFRIVOQBR-LJQANCHMSA-N n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3-oxo-1h-isoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2)=O)=C1 QDZOBXFRIVOQBR-LJQANCHMSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Virology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Biotechnology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK00977095T 1999-11-12 2000-11-09 Farmaceutisk aktive isoindolinderivater DK1228071T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US16516899P	1999-11-12	1999-11-12
US59034400A	2000-06-08	2000-06-08
US09/708,199 US6667316B1 (en)	1999-11-12	2000-11-08	Pharmaceutically active isoindoline derivatives
PCT/US2000/030770 WO2001034606A1 (fr)	1999-11-12	2000-11-09	Derives d'isoindoline actifs d'un point de vue pharmaceutique

Publications (1)

Publication Number	Publication Date
DK1228071T3 true DK1228071T3 (da)	2007-08-06

Family

ID=27389110

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK00977095T DK1228071T3 (da)	1999-11-12	2000-11-09	Farmaceutisk aktive isoindolinderivater
DK10176420.7T DK2263669T3 (da)	1999-11-12	2000-11-09	Farmaceutisk aktive isoindolin-derivater

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK10176420.7T DK2263669T3 (da)	1999-11-12	2000-11-09	Farmaceutisk aktive isoindolin-derivater

Country Status (19)

Country	Link
US (1)	US6667316B1 (fr)
EP (4)	EP1228071B8 (fr)
JP (1)	JP5116201B2 (fr)
CN (1)	CN1325497C (fr)
AT (4)	ATE506058T1 (fr)
AU (2)	AU782409B2 (fr)
CA (1)	CA2392081C (fr)
CY (2)	CY1107610T1 (fr)
DE (1)	DE60034139T2 (fr)
DK (2)	DK1228071T3 (fr)
ES (4)	ES2282147T3 (fr)
FI (1)	FI119931B (fr)
HK (1)	HK1049158A1 (fr)
MX (1)	MXPA02004793A (fr)
NO (2)	NO323633B1 (fr)
NZ (1)	NZ519459A (fr)
PT (2)	PT1228071E (fr)
SI (1)	SI1228071T1 (fr)
WO (1)	WO2001034606A1 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6429221B1 (en)	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
US6518281B2 (en) *	1995-08-29	2003-02-11	Celgene Corporation	Immunotherapeutic agents
NZ334148A (en) *	1996-08-12	2001-12-21	Celgene Corp	3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US8030343B2 (en) *	2000-06-08	2011-10-04	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US7491634B2 (en) *	2006-04-28	2009-02-17	Asm International N.V.	Methods for forming roughened surfaces and applications thereof
CN1518447A (zh)	2001-04-23	2004-08-04	��Ǵ�ѧר��	作为抗血管生成剂的新的苯邻二甲酰亚胺模拟物的合成和评估
NZ531294A (en) *	2001-08-06	2005-11-25	Childrens Medical Center	Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US6962940B2 (en) *	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2258363A1 (fr) *	2002-05-17	2010-12-08	Celgene Corporation	Compositions pour le traitement des cancers
CN1713905A (zh)	2002-10-15	2005-12-28	细胞基因公司	用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
US20050203142A1 (en) *	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) *	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
AU2003285107B2 (en) *	2002-10-31	2008-01-10	Celgene Corporation	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
US7776907B2 (en) *	2002-10-31	2010-08-17	Celgene Corporation	Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
MXPA05004777A (es) *	2002-11-06	2005-07-22	Celgene Corp	Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
TW200501945A (en) *	2002-11-06	2005-01-16	Celgene Corp	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
EP1581205A1 (fr) *	2002-11-18	2005-10-05	Celgene Corporation	Compositions comprenant un (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide et methodes d'utilisation de ces compositions
NZ540546A (en) *	2002-11-18	2008-03-28	Celgene Corp	Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
BR0317885A (pt) *	2002-12-30	2005-12-06	Celgene Corp	Composto, isÈmeros s e r enantiomericamente puros do mesmo, composição farmacêutica e métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa, de tratar ou prevenir mds, de tratar doença mieloproliferativa, angiogênese indesejada, câncer, uma doença, inflamação dos pulmões, depressão, distúrbio pulmonar obstrutivo crÈnico, doença inflamatória do intestino, dermatite atópica, psorìase, doença de crohn, artrite reumatóide, asma, eslcerose múltipla e doença cardìaca em um mamìfero e de tratar, prevenir ou controlar a sìndrome de dor regional complexa
WO2004080393A2 (fr) *	2003-03-06	2004-09-23	Celgene Corporation	Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central
US20040175382A1 (en) *	2003-03-06	2004-09-09	Schafer Peter H.	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN100427465C (zh) *	2003-03-12	2008-10-22	细胞基因公司	N-烷基-异羟肟酸-异吲哚基化合物及其药物用途
JP4713465B2 (ja)	2003-03-12	2011-06-29	セルジーンコーポレイション	７−アミド−イソインドリル化合物およびその薬学的使用
DE602004032522D1 (de) *	2003-03-12	2011-06-16	Celgene Corp	Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
US8088737B2 (en)	2003-04-04	2012-01-03	Incyte Corporation	Compositions, methods and kits relating to Her-2 cleavage
US7320992B2 (en) *	2003-08-25	2008-01-22	Amgen Inc.	Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CA2543132A1 (fr) *	2003-10-23	2005-05-19	Celgene Corporation	Procedes d'utilisations et compositions comprenant des medicaments selectifs inhibiteurs de la cytokine utilises dans le traitement, la modification et la gestion de la douleur
US20050142104A1 (en) *	2003-11-06	2005-06-30	Zeldis Jerome B.	Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
US20080213213A1 (en) *	2004-04-14	2008-09-04	Zeldis Jerome B	Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
MXPA06012279A (es) *	2004-04-23	2007-01-31	Celgene Corp	Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
BRPI0418801A (pt) *	2004-05-05	2007-10-16	Celgene Corp	métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit
JP2007536221A (ja) *	2004-05-05	2007-12-13	セルジーン・コーポレーション	骨髄増殖性疾患を治療及び管理するための選択的サイトカイン阻害薬の使用方法及びそれを含む組成物
WO2006004191A1 (fr) *	2004-07-05	2006-01-12	Astellas Pharma Inc.	Derivés de pyrrolopyridazine qui inhibent la pde iv et le tnf alpha
US7244759B2 (en) *	2004-07-28	2007-07-17	Celgene Corporation	Isoindoline compounds and methods of making and using the same
CA2578789A1 (fr) *	2004-09-03	2006-03-16	Celgene Corporation	Composes heterocycliques substitues et leurs utilisations
US20070190070A1 (en) *	2004-09-03	2007-08-16	Zeldis Jerome B	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2006050057A2 (fr) *	2004-10-28	2006-05-11	Celgene Corporation	Methodes et compositions utilisant des modulateurs de pde4 pour le traitement et la gestion de lesions du systeme nerveux central
KR20070092276A (ko) *	2004-12-13	2007-09-12	셀진 코포레이션	Ｐｄｅ４ 조절인자를 포함하는 조성물 및 이의 기도염의치료 또는 예방을 위한 용도
US20070155791A1 (en) *	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
JP2011515469A (ja) *	2008-03-24	2011-05-19	セルジーンコーポレイション	シクロプロピル−ｎ−｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシフェニル）−２−（メチルスルホニル）エチル］−３−オキソイソインドリン−４−イル｝カルボキサミドを使用した乾癬又は乾癬性関節炎の治療
EP2344479B1 (fr) *	2008-09-23	2015-04-08	Georgetown University	Dérivés de 1,2-benzisothiazolinone et d'isoindolinone
US8563580B2 (en) *	2008-09-23	2013-10-22	Georgetown University	Flavivirus inhibitors and methods for their use
EP2395995A1 (fr)	2009-02-10	2011-12-21	Celgene Corporation	Méthodes d'utilisation et compositions comprenant des modulateurs de pde4 pour traiter, prévenir, et gérer la tuberculose
CN108059635B (zh)	2009-05-14	2021-10-01	天津合美医药科技有限公司	噻吩衍生物
ES2469849T3 (es)	2009-06-18	2014-06-20	Concert Pharmaceuticals Inc.	Derivados deuterados de isoindolin-1,3-diona como inhibidores de PDE4 y TNF-alfa
ES2451350T3 (es)	2009-10-09	2014-03-26	Celgene Corporation	Procedimientos para la preparación de compuestos de 2-(1-feniletil)isoindolin-1-ona
BR112012015129A2 (pt) *	2009-12-22	2019-09-24	Celgene Corp	"composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio"
MX341050B (es)	2010-04-07	2016-08-05	Celgene Corp *	Metodos para tratar infeccion viral respiratoria.
EP2583098B1 (fr)	2010-06-15	2018-08-08	Celgene Corporation	Biomarqueurs pour le traitement du psoriasis
EP2663549B1 (fr) *	2011-01-10	2018-03-14	Celgene Corporation	Dérivés d'isoindoline phénétylsulfone comme inhibiteurs de pde 4 et/ou de cytokines
JP2014505054A (ja) *	2011-01-10	2014-02-27	セルジーンコーポレイション	シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの経口剤形
WO2012097116A2 (fr)	2011-01-14	2012-07-19	Celgene Corporation	Isotopologues de dérivés d'isoindole
ES2711100T3 (es)	2011-03-07	2019-04-30	Celgene Corp	Métodos para tratar enfermedades usando compuestos isoindolina
WO2013025897A1 (fr)	2011-08-16	2013-02-21	Georgetown University	Méthodes de traitement d'infections bactériennes au moyen de dérivés de 1,2-benzisothiazolinone et d'isoindolinone
RU2627471C2 (ru) *	2011-09-14	2017-08-08	Селджин Корпорейшн	Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
US8981117B2 (en)	2012-09-14	2015-03-17	Celgene Corporation	Processes for the preparation of isoindole compounds and isotopologues thereof
WO2015175956A1 (fr)	2014-05-16	2015-11-19	Celgene Corporation	Compositions et procédés de traitement de maladies cardiovasculaires athérosclérotiques à l'aide de modulateurs de pde4
MX2016014384A (es)	2014-06-23	2017-01-20	Celgene Corp	Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
BR112017019850A2 (pt) *	2015-03-19	2018-06-05	Cipla Ltd	?processo melhorado para a preparação de apremilast?
WO2017070291A1 (fr)	2015-10-21	2017-04-27	Celgene Corporation	Modulateurs de pde4 pour le traitement et la prévention du syndrome inflammatoire de reconstitution immunitaire (iris)
HU231259B1 (hu)	2016-02-04	2022-06-28	Egyt Gyogyszervegyeszeti Gyar	Eljárás pomalidomide elõállítására
AU2017317123B9 (en) *	2016-08-22	2021-11-25	Medshine Discovery Inc.	PDE4 inhibitor
CN107698484B (zh) *	2017-11-13	2020-05-19	广东中科药物研究有限公司	一种来那度胺的衍生物的制备方法与应用
WO2019142124A1 (fr)	2018-01-17	2019-07-25	Cadila Healthcare Limited	Compositions pharmaceutiques pour le traitement du vitiligo
AU2019254962C1 (en)	2018-04-17	2023-04-27	Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd	Isoindole derivatives
WO2020020101A1 (fr) *	2018-07-22	2020-01-30	上海星叶医药科技有限公司	Composé de benzisosélénazolidone amine, son procédé de préparation et son utilisation
CN110003084B (zh) *	2019-03-15	2022-08-02	华南师范大学	一种同时具有力致发光和聚集诱导发光特性的有机圆偏振发光材料及其制备方法与应用
CN111170925B (zh) *	2020-01-09	2023-01-17	常州大学	作为pde2/4双重抑制剂的邻苯二甲酰亚胺类化合物及其制备方法
CN117203196A (zh) *	2020-12-14	2023-12-08	拜欧斯瑞克斯公司	Pde4降解剂、药物组合物和治疗应用
WO2022194096A1 (fr) *	2021-03-15	2022-09-22	深圳福沃药业有限公司	Antagoniste du récepteur des oestrogènes
CN114790164B (zh) *	2021-08-13	2022-12-27	苏州璞正医药有限公司	一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
CN116354857B (zh) *	2023-03-01	2025-01-21	中国人民解放军海军军医大学	一种β-氨基砜及其衍生物的制备方法
CN120000645A (zh) *	2023-11-14	2025-05-16	赣州和美药业股份有限公司	白塞综合征的治疗
WO2025103430A1 (fr) *	2023-11-14	2025-05-22	天津合美医药科技有限公司	Prévention ou traitement du syndrome de sjögren

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4173652A (en)	1976-12-18	1979-11-06	Akzona Incorporated	Pharmaceutical hydroxamic acid compositions and uses thereof
SE434638B (sv)	1980-06-06	1984-08-06	Lekemedelsfabriken Medica Ab	Nya terapeutiska verdefulla taurinderivat och deras framstellning
US4820828A (en)	1987-03-04	1989-04-11	Ortho Pharmaceutical Corporation	Cinnamohydroxamic acids
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
US5605914A (en)	1993-07-02	1997-02-25	Celgene Corporation	Imides
US5463063A (en) *	1993-07-02	1995-10-31	Celgene Corporation	Ring closure of N-phthaloylglutamines
US5801195A (en)	1994-12-30	1998-09-01	Celgene Corporation	Immunotherapeutic aryl amides
US5703098A (en) *	1994-12-30	1997-12-30	Celgene Corporation	Immunotherapeutic imides/amides
US6429221B1 (en) *	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
CA2227237C (fr)	1995-07-26	2005-12-13	Pfizer Inc.	Derives d'acide hydroxamique n-(aroyl)glycine et composes apparentes
US5728844A (en) *	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
US5728845A (en) *	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic nitriles
US5658940A (en)	1995-10-06	1997-08-19	Celgene Corporation	Succinimide and maleimide cytokine inhibitors
PT871439E (pt)	1996-01-02	2004-08-31	Aventis Pharma Inc	Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
WO1998005635A1 (fr) *	1996-08-07	1998-02-12	Darwin Discovery Limited	Derives de l'acide hydroxamique et de l'acide carboxylique dotes d'une activite inhibitrice vis a vis des mmp et du tnf
NZ334148A (en)	1996-08-12	2001-12-21	Celgene Corp	3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
HUP0003761A3 (en) *	1997-07-31	2001-04-28	Celgene Corp Warren	Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels

2000
- 2000-11-08 US US09/708,199 patent/US6667316B1/en not_active Expired - Lifetime
- 2000-11-09 CN CNB00818254XA patent/CN1325497C/zh not_active Expired - Fee Related
- 2000-11-09 ES ES00977095T patent/ES2282147T3/es not_active Expired - Lifetime
- 2000-11-09 AT AT06009632T patent/ATE506058T1/de not_active IP Right Cessation
- 2000-11-09 EP EP00977095A patent/EP1228071B8/fr not_active Expired - Lifetime
- 2000-11-09 MX MXPA02004793A patent/MXPA02004793A/es active IP Right Grant
- 2000-11-09 ES ES06009632T patent/ES2363933T3/es not_active Expired - Lifetime
- 2000-11-09 ES ES10176420T patent/ES2380574T3/es not_active Expired - Lifetime
- 2000-11-09 EP EP10176420A patent/EP2263669B1/fr not_active Expired - Lifetime
- 2000-11-09 DK DK00977095T patent/DK1228071T3/da active
- 2000-11-09 CA CA002392081A patent/CA2392081C/fr not_active Expired - Fee Related
- 2000-11-09 NZ NZ519459A patent/NZ519459A/en not_active IP Right Cessation
- 2000-11-09 JP JP2001536553A patent/JP5116201B2/ja not_active Expired - Fee Related
- 2000-11-09 DE DE60034139T patent/DE60034139T2/de not_active Expired - Lifetime
- 2000-11-09 AU AU14780/01A patent/AU782409B2/en not_active Ceased
- 2000-11-09 DK DK10176420.7T patent/DK2263669T3/da active
- 2000-11-09 AT AT10176390T patent/ATE544451T1/de active
- 2000-11-09 AT AT00977095T patent/ATE357913T1/de active
- 2000-11-09 EP EP10176390A patent/EP2255801B1/fr not_active Expired - Lifetime
- 2000-11-09 SI SI200030951T patent/SI1228071T1/sl unknown
- 2000-11-09 PT PT00977095T patent/PT1228071E/pt unknown
- 2000-11-09 ES ES10176390T patent/ES2381174T3/es not_active Expired - Lifetime
- 2000-11-09 PT PT10176420T patent/PT2263669E/pt unknown
- 2000-11-09 HK HK03100819.6A patent/HK1049158A1/zh unknown
- 2000-11-09 AT AT10176420T patent/ATE544452T1/de active
- 2000-11-09 WO PCT/US2000/030770 patent/WO2001034606A1/fr not_active Ceased
- 2000-11-09 EP EP06009632A patent/EP1698334B1/fr not_active Expired - Lifetime
2002
- 2002-05-08 NO NO20022223A patent/NO323633B1/no not_active IP Right Cessation
- 2002-05-10 FI FI20020892A patent/FI119931B/fi not_active IP Right Cessation
2005
- 2005-07-07 AU AU2005202964A patent/AU2005202964B2/en not_active Ceased
2007
- 2007-03-21 NO NO20071490A patent/NO336210B1/no not_active IP Right Cessation
- 2007-04-05 CY CY20071100487T patent/CY1107610T1/el unknown
2012
- 2012-04-26 CY CY20121100399T patent/CY1112707T1/el unknown

Also Published As

Publication number	Publication date
CN1420889A (zh)	2003-05-28
JP5116201B2 (ja)	2013-01-09
ATE544451T1 (de)	2012-02-15
CY1107610T1 (el)	2013-03-13
CY1112707T1 (el)	2016-02-10
ES2282147T3 (es)	2007-10-16
DE60034139D1 (de)	2007-05-10
NO20022223L (no)	2002-07-08
AU782409B2 (en)	2005-07-28
NO20022223D0 (no)	2002-05-08
EP1228071A4 (fr)	2002-12-04
NO20071490L (no)	2002-07-08
ES2381174T3 (es)	2012-05-23
DE60034139T2 (de)	2007-12-06
FI20020892L (fi)	2002-06-20
CN1325497C (zh)	2007-07-11
HK1053467A1 (en)	2003-10-24
AU2005202964A1 (en)	2005-08-11
AU2005202964B2 (en)	2007-11-22
EP2255801A1 (fr)	2010-12-01
EP1228071A1 (fr)	2002-08-07
JP2004500346A (ja)	2004-01-08
NZ519459A (en)	2003-11-28
DK2263669T3 (da)	2012-04-23
CA2392081C (fr)	2010-01-05
FI119931B (fi)	2009-05-15
EP1698334B1 (fr)	2011-04-20
PT1228071E (pt)	2007-05-31
ES2380574T3 (es)	2012-05-16
EP1228071B8 (fr)	2012-02-29
PT2263669E (pt)	2012-04-23
WO2001034606A1 (fr)	2001-05-17
EP2255801B1 (fr)	2012-02-08
MXPA02004793A (es)	2003-10-14
SI1228071T1 (sl)	2007-08-31
EP1228071B1 (fr)	2007-03-28
CA2392081A1 (fr)	2001-05-17
ATE544452T1 (de)	2012-02-15
ES2363933T3 (es)	2011-08-19
HK1049158A1 (zh)	2003-05-02
ATE506058T1 (de)	2011-05-15
US6667316B1 (en)	2003-12-23
FI20020892A0 (fi)	2002-05-10
EP2263669B1 (fr)	2012-02-08
NO323633B1 (no)	2007-06-18
AU1478001A (en)	2001-06-06
ATE357913T1 (de)	2007-04-15
EP1698334A1 (fr)	2006-09-06
NO336210B1 (no)	2015-06-15
EP2263669A1 (fr)	2010-12-22

Publication	Publication Date	Title
ATE544452T1 (de)	2012-02-15	Pharmazeutisch aktive isoindolin-derivate
CY1123084T1 (el)	2021-10-29	Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
NO20002217D0 (no)	2000-04-28	Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
CO5580776A2 (es)	2005-11-30	Formulacion farmaceutica estable en solucion de oxaliplatino
DK0479903T3 (da)	1996-03-18	Substituerede imidazoler og deres anvendelse som angiotensin II hæmmere
ES2172143T3 (es)	2002-09-16	Combinaciones de productos activos fungicidas.
DK1206261T3 (da)	2006-07-03	Farmaceutiske præparater, der omfatter clavuansyre eller derivater deraf, til behandlingen af adfærdsmæssige sygdomme
HRP20000494B1 (en)	2009-02-28	Pharmaceutically active morpholinol
DK0998287T3 (da)	2003-09-01	Anvendelse af levobupivacain
CY1107616T1 (el)	2013-03-13	Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της
EA200101150A1 (ru)	2002-04-25	Раствор прукалоприда для перорального применения
ATE222103T1 (de)	2002-08-15	Inklusionskomplexe in waessriger loesung
RU2000104099A (ru)	2001-10-27	Средство для локальной противоревматической терапии
IT1309464B1 (it)	2002-01-23	Apparecchio per laserterapia.
DK1086695T3 (da)	2005-04-25	Antivirale præparater omfattende yohimbin som aktivt princip
ATE302582T1 (de)	2005-09-15	Haartonikum mit l-arginin als wirkstoff
IT1310896B1 (it)	2002-02-27	Articolatore per odontotecnica.
IT1311630B1 (it)	2002-03-14	Perfezionamento ad una struttura di vassoio isotermico,particolarmente per la somministrazione delle vivande alle comunita'.
ITBO990038A0 (it)	1999-01-28	Pomata per la cura delle lesioni cutanee particolarmente delle ustioni .
ES1044269Y (es)	2000-09-01	Mesa camilla desmontable.
ES1044586Y (es)	2000-09-16	Limpiazapatos perfeccionado.
ES1042703Y (es)	2000-02-16	"cuadro perfeccionado".
ITBS990062V0 (it)	1999-07-06	Trave composta per solaio.
IT247616Y1 (it)	2002-09-09	Bocchino monouso perfezionato, in particolare per narghile'.
ES1041610Y (es)	1999-12-01	Mesa extensible perfeccionada.